- Home
- FLC vs SGHT Comparison
FLC vs SGHT Comparison
Compare FLC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- SGHT
- Stock Information
- Founded
- FLC 2003
- SGHT 2011
- Country
- FLC United States
- SGHT United States
- Employees
- FLC N/A
- SGHT N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- SGHT Medical Specialities
- Sector
- FLC Finance
- SGHT Health Care
- Exchange
- FLC Nasdaq
- SGHT Nasdaq
- Market Cap
- FLC 174.2M
- SGHT 179.7M
- IPO Year
- FLC N/A
- SGHT 2021
- Fundamental
- Price
- FLC $17.18
- SGHT $4.20
- Analyst Decision
- FLC
- SGHT Buy
- Analyst Count
- FLC 0
- SGHT 8
- Target Price
- FLC N/A
- SGHT $4.16
- AVG Volume (30 Days)
- FLC 37.8K
- SGHT 129.3K
- Earning Date
- FLC 01-01-0001
- SGHT 08-07-2025
- Dividend Yield
- FLC 6.64%
- SGHT N/A
- EPS Growth
- FLC N/A
- SGHT N/A
- EPS
- FLC N/A
- SGHT N/A
- Revenue
- FLC N/A
- SGHT $76,303,000.00
- Revenue This Year
- FLC N/A
- SGHT N/A
- Revenue Next Year
- FLC N/A
- SGHT $11.22
- P/E Ratio
- FLC N/A
- SGHT N/A
- Revenue Growth
- FLC N/A
- SGHT N/A
- 52 Week Low
- FLC $12.62
- SGHT $2.03
- 52 Week High
- FLC $15.45
- SGHT $7.05
- Technical
- Relative Strength Index (RSI)
- FLC 60.93
- SGHT 61.53
- Support Level
- FLC $17.07
- SGHT $4.01
- Resistance Level
- FLC $17.19
- SGHT $4.34
- Average True Range (ATR)
- FLC 0.10
- SGHT 0.24
- MACD
- FLC 0.00
- SGHT 0.09
- Stochastic Oscillator
- FLC 74.14
- SGHT 88.62
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.